Last reviewed · How we verify

Intraperitoneal lidocaine

Cairo University · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

Intraperitoneal lidocaine is a Small molecule drug developed by Cairo University. It is currently FDA-approved. Also known as: IP Lidocaine.

Intraperitoneal lidocaine is used to study pain relief in various conditions, including post-operative pain and abdominal cancer, as seen in clinical trials such as NCT03693820. It works by blocking sodium channels, a mechanism consistent with its classification as a sodium channel alpha subunit blocker.

At a glance

Generic nameIntraperitoneal lidocaine
Also known asIP Lidocaine
SponsorCairo University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Intraperitoneal lidocaine

What is Intraperitoneal lidocaine?

Intraperitoneal lidocaine is a Small molecule drug developed by Cairo University.

Who makes Intraperitoneal lidocaine?

Intraperitoneal lidocaine is developed and marketed by Cairo University (see full Cairo University pipeline at /company/cairo-university).

Is Intraperitoneal lidocaine also known as anything else?

Intraperitoneal lidocaine is also known as IP Lidocaine.

What development phase is Intraperitoneal lidocaine in?

Intraperitoneal lidocaine is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing